Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:07:10 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:VTRS - VIATRIS INC - https://www.viatris.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VTRS - Q0.58.85·9.004.98.88-0.39-4.29,919.786,71524,8229.225  9.2699  8.83513.55  6.8518:02:4106:5915 min RT 2¢

Recent Trades - Last 10 of 24822
Time ETExPriceChangeVolume
18:02:41Q8.94-0.331
18:01:36Q8.92-0.359
17:54:13Q8.965-0.3051
17:52:21Q8.89-0.38100
17:46:44Q8.92-0.351
17:45:02Q8.89-0.38991
17:44:38Q8.90-0.376
16:46:25Q8.91-0.368
16:45:53Q8.91-0.365
16:45:43Q8.90-0.37560

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-18 06:59U:VTRSNews ReleaseViatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
2025-07-15 06:59U:VTRSNews ReleaseViatris Certified as a Great Place to Work(TM) in Canada
2025-06-26 06:55U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
2025-06-12 16:30U:VTRSNews ReleaseViatris to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-06-02 08:00U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
2025-05-27 06:59U:VTRSNews ReleaseViatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
2025-05-22 06:59U:VTRSNews ReleaseViatris to Participate in Upcoming Investor Conferences
2025-05-08 06:59U:VTRSNews ReleaseViatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
2025-05-08 06:45U:VTRSNews ReleaseViatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO(TM) Low Dose Patch for Birth Control in Women of Childbearing Potential
2025-05-08 06:30U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
2025-05-07 06:59U:VTRSNews ReleaseViatris Announces Quarterly Dividend
2025-05-05 16:30U:VTRSNews ReleaseViatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
2025-04-25 06:59U:VTRSNews ReleaseViatris to Present at the BofA Securities 2025 Healthcare Conference
2025-04-21 06:59U:VTRSNews ReleaseViatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR(TM) for the Treatment of Generalized Anxiety Disorder
2025-04-14 06:59U:VTRSNews ReleaseViatris Appoints Hemanth J. Varghese as Chief Strategy Officer
2025-04-07 06:59U:VTRSNews ReleaseViatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
2025-03-28 06:59U:VTRSNews ReleaseViatris to Report First Quarter 2025 Financial Results on May 8, 2025
2025-03-05 16:30U:VTRSNews ReleaseViatris to Present at the Barclays 27th Annual Global Healthcare Conference
2025-02-27 06:45U:VTRSNews ReleaseViatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance
2025-02-27 06:30U:VTRSNews ReleaseViatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend